Scientists injected Aedes aegypti mosquitoes that yellow yellow and dengue fever.

Scientists injected Aedes aegypti mosquitoes that yellow yellow and dengue fever, and Anopheles mosquitoes that carry malaria, with a special strain of rapidly growing Wolbachia originally found in fruit flies. They found that 10 % of A. Aegypti survived mosquitoes, and survived only 5 % of the Anopheles mosquito. Discovery News writes that dies after the original infected mosquito, [a] ll the offspring from a Wolbachia - infected female mosquitoes are also Wolbachia infection since the parasite is passed from mother to daughter.

EMEA recommends approval of First Pre - Pandemic Influenza Vaccine, EuropeThe European Medicines Agency recommends approval of the first pre-pandemic vaccine for humans against influenza caused by the H5N1 virus is. An avian influenza an avian influenza virus strain, which has the potential develop into a pandemic influenza virus humans humans.Cancer stem cells can presumably responsible for the resistance of of human cancers positively to chemotherapy and of metastatic Throwback. MT110 be in the a phase 1 clinical - to patients with in patients with pulmonary or the gastrointestinal cancers.. EpCAM present data at the AACR meetings See eliminating colorectal cancer stem of BiTE antibody MT110.

Micromet , a biopharmaceutical company developing novel, proprietary antibodies to treat cancer, inflammation and autoimmune disorders, data presented at Annual Meeting of the American Association for Cancer Research in Denver, Colorado, that their BiTE antibody MT110 can be eliminate cancer stem .

It is in one phase 2 clinical trials for the treatment by patient with acute lymphoblastic leukemia and of a phase 1 clinical trial in in patients with non-Hodgkin's lymphoma. Micromet is second BiTE antibody in clinical development be MT110 , which targets the epithelial cell adhesion molecule . The Company own all rights to MT110, autoimmune diseases in the clinical clinical trials for the treatment by patients with solid cancers. To society third clinical phase antibodies Adecatumumab also as MT201 a traditional of human monoclonal antibody which aimed EpCAM expression known to solid tumors. Micromet licensed to a quarter of Phase antibody MT293, at TRACON Pharmaceuticals, MT293 being developed in a phase 1 clinical trial for management of patients to cancers.